Clinical trial Recruiting at 1 site Observational Ages 45 to 90

Understanding cognitive outcomes after stroke

Official title: StrokeCog-BBB to Study Cognitive Outcomes Following Stroke

Run by Stanford University · NCT06116630 · Data updated 2026-11-12

This study looks at how a stroke affects thinking and memory over time in stroke patients compared to people with similar heart risks, to see if certain blood markers can help predict cognitive decline.

Quick facts

Study typeObservational
Ages45 Years to 90 Years
SexAll
Enrollment350 (estimated)
SponsorStanford University
Academic / other
Locations1 site (Palo Alto, California)
StatusRecruiting
StartedMay 17, 2022
Main results expectedDecember 31, 2027
Study endsDecember 31, 2027
Registry record updatedApril 18, 2024
Trial IDNCT06116630 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are individuals aged 45 and older with one or more vascular risk factors who have not experienced a stroke or significant brain injury.

Probably not a fit

Patients with a history of stroke, dementia, or major neurological diseases may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate cognitive outcomes in stroke patients by examining the long-term effects of stroke on brain function. Researchers will assess blood-brain barrier permeability, identify blood biomarkers related to angiogenesis, and explore their relationship with cognitive decline. Participants will undergo cognitive testing and MRIs two years apart, and their outcomes will be compared to non-stroke patients with cardiovascular risk factors. The study seeks to uncover potential mechanisms behind post-stroke dementia and establish biomarkers for predicting cognitive decline.

Why it matters

Potential benefit: If successful, this study could lead to better understanding and early identification of patients at risk for cognitive decline after a stroke.

How similar studies have gone: While there is ongoing research into post-stroke cognitive outcomes, this study's specific focus on blood-brain barrier dysfunction and biomarkers is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Aged 45 years or over
* One or more vascular risk factors (e.g. high blood pressure, diabetes or vascular disease such as angina, a previous heart attack, a heart bypass or peripheral artery disease in the legs)
* Established vascular disease (previous MI, angina, vascular stent in the peripheral bed)
* Sufficiently fluent in written and spoken English
* Living independently in the community
* Willing/able to give consent to study participation.

Exclusion Criteria:

* Current treatment with IL-1 blockade or established immune-suppressant therapy (e.g. IL-1Ra or IL-1 antibodies), or treatment within the last 3 months
* Currently participating in a clinical trial of investigation medicinal product (CTIMP) or device trial.
* No history of any previous ischaemic or haemorrhagic stroke, a mini-stroke or a serious brain injury
* Do not have dementia
* Renovascular Disease
* Major neurological disease (immune mediated, previous brain tumors)

Where it's running

  • Stanford University Hospital
    Palo Alto, California, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.